Who are Oxaliplatin + 5-Fluorouracil/Leucovorin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): oxaliplatin plus capecitabine, Oxaliplatin;Capecitabine, Pemetrexed + carboplatin, TS-1, oxaliplatin, platinum-based dual-agent chemotherapy, atezolizumab + avastin + platinum-based chemotherapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oxaliplatin-5-fluorouracil-leucovorin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Oxaliplatin + 5-Fluorouracil/Leucovorin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oxaliplatin + 5-Fluorouracil/Leucovorin (Oxaliplatin + 5-Fluorouracil/Leucovorin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Platinum-based chemotherapy combination; antimetabolite. Area: Oncology.

phase 3 Platinum-based chemotherapy combination; antimetabolite DNA (oxaliplatin); thymidylate synthase (5-fluorouracil) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Oxaliplatin + 5-Fluorouracil/Leucovorin (Oxaliplatin + 5-Fluorouracil/Leucovorin) — First Affiliated Hospital of Zhejiang University. This combination uses oxaliplatin (a platinum-based DNA crosslinker) plus 5-fluorouracil and leucovorin (a thymidylate synthase inhibitor with a folate cofactor) to damage cancer cell DNA and disrupt nucleotide synthesis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Oxaliplatin + 5-Fluorouracil/Leucovorin TARGET	Oxaliplatin + 5-Fluorouracil/Leucovorin	First Affiliated Hospital of Zhejiang University	phase 3	Platinum-based chemotherapy combination; antimetabolite	DNA (oxaliplatin); thymidylate synthase (5-fluorouracil)
oxaliplatin plus capecitabine	oxaliplatin plus capecitabine	LiNing	marketed	Platinum-based chemotherapy combination	DNA (oxaliplatin); thymidylate synthase (capecitabine/5-FU)
Oxaliplatin;Capecitabine	Oxaliplatin;Capecitabine	Hebei Medical University	marketed	Platinum-based chemotherapy combination; antimetabolite	DNA (oxaliplatin); thymidylate synthase (capecitabine/5-FU)
Pemetrexed + carboplatin	Pemetrexed + carboplatin	AstraZeneca	phase 3	Antifolate antimetabolite + platinum-based chemotherapy combination	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase (pemetrexed); DNA (carboplatin)
TS-1, oxaliplatin	TS-1, oxaliplatin	Samsung Medical Center	phase 3	Fluoropyrimidine + platinum-based chemotherapy combination	Thymidylate synthase; DNA (platinum crosslinking)
platinum-based dual-agent chemotherapy	platinum-based dual-agent chemotherapy	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	phase 3	Platinum-based chemotherapy combination
atezolizumab + avastin + platinum-based chemotherapy	atezolizumab + avastin + platinum-based chemotherapy	ARCAGY/ GINECO GROUP	phase 3	PD-L1 inhibitor + VEGF inhibitor + platinum-based chemotherapy combination	PD-L1, VEGF, DNA (platinum adducts)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Platinum-based chemotherapy combination; antimetabolite class)

First Affiliated Hospital of Zhejiang University · 1 drug in this class
Hebei Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oxaliplatin + 5-Fluorouracil/Leucovorin — Competitive Intelligence Brief. https://druglandscape.com/ci/oxaliplatin-5-fluorouracil-leucovorin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab